ARCA biopharma (id:5962 ABIO)
20.75 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 3:37:44 PM)
Exchange closed, opens in 1 day 17 hours
About ARCA biopharma
Market Capitalization 34.82M
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
| Headquarters (address) |
10170 Church Ranch Way Westminster 80021 CO United States |
| Phone | 720 940 2200 |
| Website | https://www.arcabio.com |
| Employees | 3 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ABIO |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 18.72 - 53.88 |
| Market Capitalization | 34.82M |
| Dividend yield forward | 31.02 % |
| Dividend yield forward United States (ID:6, base:1865) | 4.13 % |
| P/E trailing | -55.41 |
| P/E forward | -3.27 |
| Price/Book | 12.83 |
| Beta | 0.895 |
| EPS | -5.88 |
| EPS United States (ID:6, base:3402) | 24.25 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: ARCA biopharma has raised their dividend 31.02 years in a row. This is below the 41490.575400 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: ARCA biopharma has raised their dividend 31.02 years in a row. This is below the 41490.575400 year average in the 'Biotechnology' industry